imipenem | CMAC

imipenem

In vitro activity of biapenem and other carbapenems against Russian clinical isolates of Pseudomonas aeruginosa, Acinetobacter spp., and Enterobacterales

Objective. To evaluate in vitro activity of biapenem and other clinically available carbapenems against Russian clinical isolates of Enterobacterales, Pseudomonas aeruginosa и Acinetobacter spp., including isolates with acquired fermentative mechanisms of resistance to β-lactams. Materials and Methods. A total of 3139 Enterobacterales isolates, 793 P. aeruginosa isolates and 634 Acinetobacter spp. isolates from hospitalized patients in 63 hospitals from 35 Russian cities were included in the study during 2018-2019. Minimal inhibitory concentrations (MIC) for biapenem and other antimicrobials were determined in accordance with ISO 20776-1:2006.

20-Year History of Carbapenems: Current Microbiological and Clinical Aspects

The carbapenems are one of the most important classes of antimicrobial agents with an exceptionally broad spectrum of in vitro activity in association with low toxicity and beneficial pharmacokinetic parameters. Spectrum of activity of imipenem, …

Use of Carbapenems in Clinical Practice: When, Which and How Long?

Carpabenems (imipenem, meropenem, ertapenem) are currently one of the antibiotic classes that exhibit the broadest spectrum of activity and characterized by the low resistance rates of clinically significant pathogens. This article is an attempt to …

Carbapenems: Myths and Reality

This paper presents analysis of microbiological, clinical and pharmacoeconomic studies of carbapenems. Use of carbapenems during the last two decades was not associated with emergence of resistance to these agents among clinically significant human …